Drug Trials Snapshots: PENPULIMAB-KCQX // Drug Trials Snapshot: VANRAFIA

https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-penpulimab-kcqx PENPULIMAB-KCQX is a programmed death receptor-1 (PD-1)–blocking antibody and is available by prescription. PENPULIMAB-KCQX is used with cisplatin or carboplatin and gemcitabine to treat adult patients with metastatic or recurrent, locally advanced non-keratinizing nasopharyngeal cancer (NPC). PENPULIMAB-KCQX is also used as a single agent for adult patients with recurrent metastatic non-keratinizing NPC with disease progression on or after a platinum-containing chemotherapy and at least one other prior line of therapy. Drug Trials Snapshot: VANRAFIA VANRAFIA (atrasentan) VANRAFIA is an endothelin type A receptor antagonist that is indicated to reduce proteinuria in adults with primary immunoglobulin A (IgA) nephropathy at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-vanrafia